Haematopoietic stem cell transplantation for autoimmune diseases

@article{Swart2017HaematopoieticSC,
  title={Haematopoietic stem cell transplantation for autoimmune diseases},
  author={Joost F Swart and Eveline M. Delemarre and Femke van Wijk and Jaap Jan Boelens and J{\"u}rgen H. E. Kuball and Jacob M. van Laar and Nico M Wulffraat},
  journal={Nature Reviews Rheumatology},
  year={2017},
  volume={13},
  pages={244-256}
}
Autologous haematopoietic stem cell transplantation (HSCT) is the only treatment that is able to induce long-term, drug-free and symptom-free remission in several refractory autoimmune rheumatic diseases. Over 3,000 HSCT procedures for rheumatic and nonrheumatic severe autoimmune diseases have been performed worldwide. Specific conditioning regimens are currently used to eradicate the autoreactive immunological memory of patients. Although in vivo immune cell depletion with antithymocyte… Expand
Haematopoietic stem cell transplants: principles and indications.
TLDR
An overview of autologous and allogeneic haematopoietic stem cell transplantation including disease indications, the individual steps of the procedure and outcome, and highlights achievements in the treatment of autoimmune diseases is provided. Expand
Resetting the T Cell Compartment in Autoimmune Diseases With Autologous Hematopoietic Stem Cell Transplantation: An Update
TLDR
There is currently a knowledge gap regarding the immune response in tissue sites post-aHSCT, as well as disease-specific factors that may determine remission or relapse, and future studies on lymphocyte dynamics and function may pave the way for optimized conditioning regimens with a more individualized approach. Expand
Hematopoietic stem cell transplantation for autoimmune diseases: more than just prolonged immunosuppression
  • A. Tyndall
  • Biology, Medicine
  • Current opinion in hematology
  • 2018
TLDR
For the first time, it has been demonstrated that strategies exist which may permanently reprogram an autoaggressive immune system to one of self-tolerance independent of ongoing immunosuppression. Expand
Application of stem cell transplantation to autoimmune diseases.
TLDR
The aim of HSCT is to 'reset' one's immune system into a naïve and self-tolerant state through immune depletion and regulation, which requires careful patient selection, close collaboration between physicians and expertise of transplant team to ensure optimal outcome. Expand
Thymus Rejuvenation After Autologous Hematopoietic Stem Cell Transplantation in Patients with Autoimmune Diseases
TLDR
Investigation should be made to improve the knowledge about immune mechanisms involved in AHSCT for AD and to unravel biomarkers of post-transplantation outcomes, which are associated with favorable clinical outcomes. Expand
Autologous ATG-free hematopoietic stem cell transplantation for refractory autoimmune rheumatic diseases: a Latin American cohort
TLDR
HSCT is a viable treatment alternative for selected patients with severe therapy-resistant ARDs, as an improvement in disease management and quality of life was documented, and the need remains to elucidate the characteristics of the optimal HSCT candidate, as well as the adequate conditioning regimen when ATG is not available. Expand
Haematopoietic stem cell transplantation in systemic sclerosis
TLDR
Hematopoietic stem cell transplantation should be proposed for carefully selected patients with early rapidly progressive diffuse SSc whose clinical picture portends a poor prognosis for survival, but yet lacks advanced organ involvement. Expand
Haematopoietic stem cell transplantation in paediatric rheumatic disease
TLDR
Careful patient and donor selection, timing of the transplant earlier in the course of disease rather than the ‘last resort’ and choosing the most suitable conditioning regimen for each individual patient are the major factors favouring successful outcome. Expand
Autologous Hematopoietic Stem Cell Transplantation for Autoimmune Diseases: From Mechanistic Insights to Biomarkers
TLDR
AHSCT for AD has entered a new era and researchers of this field should work to identify robust predictive, prognostic, treatment-response biomarkers and to establish new guidelines for immune monitoring studies and combined therapeutic interventions to further improve the AHSCT protocols and their therapeutic efficacy. Expand
Hematopoietic stem cell therapy for autoimmune diseases - Clinical experience and mechanisms.
TLDR
The current role and future perspectives of HSCT in AD are discussed, focusing on recent published clinical and scientific studies and recommendations in the field. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 233 REFERENCES
Complications of autologous hematopoietic stem cell transplantation for patients with autoimmune diseases
TLDR
The steadily increasing knowledge about specific complications occurring in patients with ADs after HSCT has led to the adaption of treatment protocols and has already reduced toxicity. Expand
Immunological reconstitution after autologous stem cell transplantation in patients with refractory systemic autoimmune diseases
TLDR
AHSCT can be a salvage therapeutic modality in autoimmune patients who are refractory to other conventional therapies, and approximately 5–6 months were required for the reconstitution of the peripheral immune network. Expand
Haematopoietic stem cell transplantation for poor-prognosis systemic sclerosis.
TLDR
In some patients, sustained complete normalization of skin changes, reversal of positive autoantibody status and withdrawal of immunosuppressive medication were observed, attest to the profound effects of HSCT. Expand
Autologous stem cell transplantation aids autoimmune patients by functional renewal and TCR diversification of regulatory T cells.
TLDR
Data indicate that HSCT-mediated amelioration of autoimmune disease involves renewal of the Treg pool, and Treg therapy may hamper development of long-term tolerance and should be approached with caution in the clinical autologous setting. Expand
Stem cell transplantation for autoimmune disorders. Immune reconstitution.
TLDR
A continued, close collaboration between scientists and physicians should both improve the outcomes of HSCT and also provide important pathogenic information about the diseases under treatment. Expand
Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis.
TLDR
It is proposed that a favourably modified balance of regulatory and pro-inflammatory lymphocytes underlies the suppression of central nervous system inflammation in patients with multiple sclerosis following non-myeloablative autologous haematopoietic stem cell transplantation with a conditioning regimen consisting of cyclophosphamide and alemtuzumab. Expand
Haematopoietic stem cell transplantation in the treatment of severe autoimmune disease: results from phase I/II studies, prospective randomized trials and future directions
TLDR
The study of immune reconstitution and gene expression pre and post HSCT is being undertaken to further understand the mechanism of autoimmunity. Expand
Bone Marrow Stem Cells and Stromal Cells in Autoimmune Cytopenias
TLDR
Using flow cytometry and in vitro culture assays, it is shown that patients with primary AIC display increased number of BM CD34 + cells in response to abnormally high production of granulocyte-colony stimulating factor by BM stroma, and patients with AIC secondary to systemic AID display increased apoptosis of BM progenitor cells. Expand
T cell repertoire following autologous stem cell transplantation for multiple sclerosis.
TLDR
It is found that HSCT has distinctive effects on CD4+ and CD8+ T cell repertoires, and TCR characterization during immunomodulatory treatment is both feasible and informative, and may enable monitoring of pathogenic or protective T cell clones following HSCT and cellular therapies. Expand
T‐cell responses after haematopoietic stem cell transplantation for aggressive relapsing–remitting multiple sclerosis
Autologous haematopoietic stem cell transplantation (HSCT) for relapsing–remitting multiple sclerosis is a potentially curative treatment, which can give rise to long‐term disease remission. However,Expand
...
1
2
3
4
5
...